Free Trial

Y-mAbs Therapeutics (YMAB) Earnings Date, Estimates & Call Transcripts

Y-mAbs Therapeutics logo
$10.97 -0.82 (-6.96%)
(As of 12:36 PM ET)

Y-mAbs Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Mar. 6Estimated
Actual EPS
(Nov. 8)
-$0.16 Missed By -$0.02
Consensus EPS
(Nov. 8)
-$0.14

Y-mAbs Therapeutics announced Q3 2024 earnings on November 8, 2024, reporting an EPS of -$0.16, which missed the consensus estimate of -$0.14 by $0.02. Quarterly revenue was reported to be $18.46 million, below analyst estimates of $23.38 million. With a trailing EPS of -$0.54, Y-mAbs Therapeutics' earnings are expected to grow next year, from ($0.64) to ($0.49) per share.

YMAB Upcoming Earnings

Y-mAbs Therapeutics' next earnings date is estimated for Thursday, March 6, 2025, based off prior year's reporting schedules.

Get Y-mAbs Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

YMAB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

YMAB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Y-mAbs Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.22-$0.11-$0.17
Q2 20242-$0.14-$0.11-$0.13
Q3 20242-$0.15-$0.09-$0.12
Q4 20242-$0.15-$0.06-$0.11
FY 20248-$0.66-$0.37-$0.52
Q1 20251-$0.16-$0.16-$0.16
Q2 20252-$0.15-$0.06-$0.11
Q3 20252-$0.15-$0.07-$0.11
Q4 20252-$0.16-$0.07-$0.12
FY 20257($0.62)($0.36)($0.49)

Y-mAbs Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
3/6/2025
(Estimated)
-------
11/8/2024Q3 2024-$0.14-$0.16 -$0.02-$0.16$23.38M$18.46M
8/12/2024Q2 2024-$0.13-$0.21 -$0.08-$0.21$23.09M$22.80M
5/7/2024Q1 2024-$0.12-$0.15 -$0.03-$0.15$22.06M$19.93M
2/29/2024Q4 2023-$0.19-$0.02+$0.17-$0.02$21.72M$23.36M
11/13/2023Q3 2023-$0.16-$0.18 -$0.02-$0.18$20.56M$20.45M
8/10/2023Q2 2023-$0.24-$0.14+$0.10-$0.14$19.04M$20.75M
5/8/2023Q1 2023-$0.31-$0.15+$0.16-$0.15$15.55M$20.30M
3/31/2023Q4 2022-$0.44$0.03+$0.47$0.03$20.35M$31.45M

Y-mAbs Therapeutics Earnings - Frequently Asked Questions

Y-mAbs Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates. Learn more on YMAB's earnings history.

Y-mAbs Therapeutics updated its FY 2024 earnings guidance on Friday, November, 8th. The company issued revenue guidance of $87.0 million-$95.0 million, compared to the consensus revenue estimate of $91.7 million.

In the previous quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) missed the analysts' consensus estimate of ($0.14) by $0.02 with a reported earnings per share (EPS) of ($0.16). Learn more on analysts' earnings estimate vs. YMAB's actual earnings.

The conference call for Y-mAbs Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Y-mAbs Therapeutics's latest earnings report can be read online.
Read Transcript

Y-mAbs Therapeutics (NASDAQ:YMAB) has a recorded annual revenue of $84.82 million.

Y-mAbs Therapeutics (NASDAQ:YMAB) has a recorded net income of -$21.43 million. YMAB has generated -$0.54 earnings per share over the last four quarters.

Y-mAbs Therapeutics's earnings are expected to grow from ($0.64) per share to ($0.49) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:YMAB) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners